A Comparison of PRC-063 and Lisdexamfetamine in the Driving Performance of Adults With ADHD

Young adult drivers with Attention Deficit Hyperactivity Disorder (ADHD) will be compared on
a driving simulator after taking PRC-063 or LDX in a repeated-measure, randomized,
doubleblind, crossover study design. Each subject will be randomized to receive up to a
21-day course of PRC-063 followed by up to a 21 day course of LDX or vice versa. There will
be no washout between treatments. On days 1 through 7, subjects will receive the lowest dose
(45 mg of PRC-063 or 30 mg of LDX) of study medication. On days 8 through 14, subjects will
receive the middle dose (70 mg of PRC-063 or 50 mg of LDX). On days 15 through 21, subjects
will receive the highest dose (100 mg of PRC-063 or 70 mg of LDX). During Days 1 through 21,
if a subject is responding satisfactorily to medication, he or she may remain on that daily
dose. Driving laboratory testing will be conducted between Day 17 and Day 21. Following the
laboratory testing, the subject will begin a second titration of the alternate treatment,
starting on Day 22 through Day 28 at the lowest dose (45 mg of PRC-063 or 30 mg of LDX) of
study medication, Day 29 through Day 35 on the middle dose (70 mg of PRC-063 or 50 mg of
LDX) and Day 36 through Day 42 on the highest dose (100 mg of PRC-063 or 70 mg of LDX).
During Days 22 through 42, if a subject is responding satisfactorily to medication, he or
she may remain on that daily dose. Following titration with the second treatment, subjects
will attend a second driving laboratory testing, conducted between Day 38 to Day 42.
Subjects will subsequently attend a safety and study termination visit.

Inclusion Criteria:

Male or non-pregnant, non-nursing female at least 18 years of age and less than or equal
to 25 years of age with a valid driver's license and at least six months of driving
experience with driving activity at least twice per week.

ADHD diagnosis, inattentive, hyperactive/impulsive or combined, as defined by the
Diagnostic and Statistical Manual of Mental Disorders, 5th Edition (DSM-5) based on
clinician assessment using the Structured Clinical Interview for DSM Disorders (SCID).

Dissatisfaction with his or her current pharmacological therapy for treatment of ADHD or
not currently receiving pharmacological therapy for ADHD. Inclusion of subjects naïve to
pharmacological therapy for ADHD is permitted.

Exclusion Criteria:

Known to be non-responsive to methylphenidate or lisdexamfetamine treatment. Nonresponse
is defined as methylphenidate or lisdexamfetamine use at various doses for a phase of at
least four weeks at each dose with little or no clinical benefit in the last 10 years.

Having a history of motion, sea or big screen (e.g. IMAX) sickness, in order to avoid
possible Simulation Adaptation Syndrome.

Subject has a known family history of sudden cardiac death or ventricular arrhythmia.